Table SI. Comorbidities of the tested group.

Comorbidities	Non-infected subjects, n (%)	Previously infected subjects, n (%)	Total sample, n (%)
Cardiovascular disease	5 (9)	1 (6)	6 (9)
Arterial hypertension	3 (6)	1 (6)	4 (6)
Ischemic coronary heart disease	1 (2)	0 (0)	1 (1)
Atrial fibrillation	1 (2)	0 (0)	1 (1)
Back pain	0 (0)	1 (6)	1 (1)
Endometriosis	1 (2)	0 (0)	1 (1)
Allergy	2 (4)	0 (0)	2 (3)
Chronic obstructive pulmonary disease	1 (2)	0 (0)	1 (1)
Diabetes	3 (6)	0 (0)	3 (4)
Type 1 diabetes	1 (2)	0 (0)	1 (1)
Type 2 diabetes	2 (4)	0 (0)	2
Non-immune thyroidian disease	2 (4)	1 (6)	3 (4)
Hypothyroidy	2 (4)	1 (6)	3 (4)
Adenoma of the thyroid	0 (0)	1 (6)	1 (1)
Autoimmune disease	2 (4)	2 (13)	4
Chronic autoimmune thyroiditis	2 (4)	1 (6)	3 (4)
Lichen planus	1 (2)	0 (0)	1 (1)
Ankylosing spondylitis	0 (0)	1 (6)	1 (1)
Minor thalassemia	0 (0)	1 (6)	1 (1)
Overweight	11 (21)	5 (31)	16 (23)
Non-obesity overweight	6	3 (19)	9 (13)
Obesity	5 (9)	2 (13)	7 (10)
Chronic venous insufficiency	2 (4)	0 (0)	2 (3)
Polycystic ovary syndrome	0 (0)	1 (6)	1 (1)
Lip carcinoma	1 (2)	0 (0)	1 (1)
Chronic inflammation	2 (4)	1 (6)	3 (4)
Ulcerative colitis	0 (0)	1 (6)	1 (1)
Chronic parodontopathy	1 (2)	0 (0)	1 (1)
Chronic rhinosinusitis	1 (2)	0 (0)	1 (1)

Table SII. Adverse effects following vaccination of the tested group.

Adverse effect	1st round non-infected subjects		2nd round non-infected subjects		1st round previously infected subjects		2nd round previously infected subjects		1st round all		2nd round all	
	Number of subjects	% 1st round non-infected subjects	Number of subjects	% 2nd round non-infected subjects	Number of subjects	% 1st round previously infected subjects	Number of subjects	% 2nd round previously infected subjects	Number of subjects	% 1st round (all)	Number of subjects	% 2nd round (all)
Axillary adenopathy	0	0	1	2	0	0	0	0	0	0	1	1
Dizziness	0	0	3	6	0	0	0	0	0	0	3	4
Arthralgia	3	6	8	15	1	6	3	19	4	6	11	16
Asthenia	5	9	16	30	1	6	3	19	6	9	19	28
Headache	9	17	17	32	2	13	3	19	11	16	21	30
Abdominal pain	0	0	1	2	0	0	1	6	0	0	2	3
Thoracic pain	0	0	1	2	0	0	1	6	0	0	2	3
Local reactions	31	58	21	40	13	81	11	69	44	64	32	46
Local pain	31	58	21	40	13	81	11	69	44	64	32	46
Local bruising	1	2	1	2	0	0	0	0	1	1	1	1
Local erythema	1	2	0	0	0	0	0	0	1	1	0	0
Local paraesthesia	1	2	0	0	0	0	0	0	1	1	0	0
Anosmia and ageusia	1	2	0	0	0	0	0	0	1	1	0	0
Flu-like syndrome	12	23	32	60	3	19	10	63	15	22	42	61
Fever	1	2	11	21	1	6	4	25	2	3	15	22
Shiver	3	6	12	23	1	6	4	25	4	6	16	23
General discomfort	0	0	1	2	1	6	1	6	1	1	2	3
Myalgia	3	6	12	23	1	6	3	19	4	6	15	22
Rhinorrhea	2	4	3	6	0	0	0	0	2	3	3	4
Cough	1	2	2	4	0	0	0	0	1	1	2	3
Sleepiness	3	6	7	13	1	6	2	13	4	6	9	13
Lipothymia	1	2	0	0	0	0	0	0	1	1	0	0

Digestive symptoms	1	2	2	4	1	6	1	6	2	3	3	4
Nausea	0	0	2	4	1	6	1	6	1	1	3	4
Vomiting	1	2	0	0	0	0	0	0	1	1	0	0
Adverse effects in all subjects	38	72	44	83	15	94	16	100	53	77	60	87